Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Conmed ( (CNMD) ) has issued an update.
On February 24, 2025, CONMED Corporation expanded its Board of Directors to nine members by appointing Mark Kaye as a director. Kaye, who brings extensive experience in finance and healthcare, will serve on the Audit and Strategy Committees. The company also declared a quarterly cash dividend of $0.20 per share, payable on April 4, 2025, to shareholders of record as of March 14, 2025. This strategic appointment and dividend announcement underscore CONMED’s commitment to leveraging financial expertise for growth and rewarding its shareholders.
More about Conmed
CONMED Corporation is a medical technology company that provides devices and equipment for surgical procedures. Its products are utilized by surgeons and healthcare professionals across various specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
YTD Price Performance: -7.99%
Average Trading Volume: 442,198
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.92B
For an in-depth examination of CNMD stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue